BIIB - Biogen - Stock Price & Dividends

Biogen Inc. is a pioneering biotechnology company that specializes in discovering, developing, manufacturing, and delivering innovative therapies for treating complex and debilitating neurological and neurodegenerative diseases worldwide.

The company's portfolio of approved products includes a range of treatments for multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which help manage the symptoms and slow the progression of this chronic disease. Additionally, Biogen offers SPINRAZA, a groundbreaking therapy for spinal muscular atrophy, and ADUHELM, a treatment for Alzheimer's disease, which is a major breakthrough in the fight against this devastating condition.

Beyond MS and Alzheimer's, Biogen's product lineup includes FUMADERM for plaque psoriasis, as well as a range of biosimilars, such as BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ, which provide cost-effective alternatives to existing treatments for various conditions. The company also offers RITUXAN and RITUXAN HYCELA for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other diseases, as well as GAZYVA for chronic lymphocytic leukemia and follicular lymphoma.

Furthermore, Biogen is actively developing a pipeline of promising new products for the treatment of MS, Alzheimer's disease, neuromuscular disorders, Parkinson's disease, and other conditions. The company is committed to advancing the boundaries of medical science and improving the lives of patients worldwide.

Biogen has established a network of strategic collaborations and partnerships with leading pharmaceutical and biotechnology companies, including Acorda Therapeutics, Alkermes, Denali Therapeutics, Eisai, Genentech, Ionis Pharmaceuticals, Samsung Bioepis, Sangamo Therapeutics, and Sage Therapeutics, among others. These partnerships enable the company to leverage its expertise and resources to accelerate the development of new treatments and bring them to market more quickly.

Founded in 1978, Biogen is headquartered in Cambridge, Massachusetts, and has grown into a global leader in the biotechnology industry, with a strong commitment to innovation, patient care, and social responsibility.